

Michael A. Davies, MD, PhD<br>Professor and Chair, Department of Melanoma Medical Oncology<br>Professor, Departments of Translational Molecular Pathology and Systems Biology<br>The Role of Oxidative Phosphorylation (OXPHOS) in Metastasis and Therapeutic Resistance in Melanoma

Dr. Davies obtained his Bachelors of Arts from the University of Texas at Austin. He completed the requirements of the combined MD/PhD Program at the University Of Texas Health Science Center Of Houston. He did his Residency in Internal Medicine at the Massachusetts General Hospital, and his Fellowship in Medical Oncology at the University of Texas MD Anderson Cancer Center. Dr. Davies is Professor and Chairman in the Department of Melanoma Medical Oncology at the University of Texas MD Anderson Cancer Center, with joint appointments in the Departments of Systems Biology, Translational Molecular Pathology, and Genomic Medicine. Dr. Davies is a physician-scientist whose research utilizes integrated approaches to study the regulation and clinical significance of oncogenic signaling networks in cancer, particularly in therapeutic resistance and in the molecular pathogenesis of brain metastases. Dr. Davies has been the principal investigator of both individual and team science peer-reviewed grants from several organizations, including the National Cancer Institute ( NCI ), the US Department of Defense (DoD), the American Society of Clinical Oncology (ASCO), the American Cancer Society (ACS), the Melanoma Research Alliance, and the Melanoma Research Foundation. He has served as the principal investigator of several clinical trials for patients with metastatic melanoma, and has authored or co-authored $>180$ original research manuscripts in peer-reviewed journals including Cell, Cancer Cell, Science, Cancer Discovery, Lancet Oncology, Cancer Research, JAMA Oncology, and Clinical Cancer Research. Dr. Davies is a member of the American Society for Clinical Investigation and the Executive Committee of the Society for Melanoma Research.

